CIViC Evidence Items
12 evidence items indexed
Evidence Level Distribution
CIViC evidence levels reflect study design quality, from A (strongest) to E (weakest).
AValidated — meta-analysis, systematic review, or major guideline
BClinical — prospective trial or retrospective cohort study
CCase study — single case report or small case series
DPreclinical — in vitro or animal model data
EInferential — computational prediction or biological rationale
Gene × Evidence Type
Count of CIViC evidence items per gene and evidence type category. Hover a column header for the type definition.
| Predictive | Diagnostic | Prognostic | Functional | Predispos. | Oncogenic | |
|---|---|---|---|---|---|---|
| BCR::ABL1 | 323 | 11 | ||||
| BRAF | 186 | 4 | 26 | 2 | 1 | |
| EGFR | 248 | 12 | 3 | 2 | ||
| EML4::ALK | 64 | |||||
| ERBB2 | 142 | 2 | ||||
| FLT3 | 55 | 2 | 21 | |||
| KIT | 102 | 3 | 7 | |||
| KRAS | 159 | 4 | 24 | 4 | ||
| PIK3CA | 156 | 16 | 4 | |||
| PTEN | 53 | 1 | 3 | 1 | 2 | 1 |
| TP53 | 52 | 40 | 100 | 2 | ||
| VHL | 5 | 2 | 3 | 635 | 15 |
Predictive:Links a variant to treatment response or resistance
Diagnostic:Supports or refutes a specific disease diagnosis
Prognostic:Informs disease progression or clinical outcome
Functional:Characterises the biological effect of a variant
Predisposing:Germline variant associated with cancer predisposition
Oncogenic:Characterises the variant's role in oncogenesis
| Level | Gene | Variant | Type | Direction | Significance | Disease | Drugs | Source |
|---|---|---|---|---|---|---|---|---|
| B | TMB | High | Predictive | Supports | Sensitivity/Response | Colorectal Cancer | Durvalumab,Tremelimumab | Loree et al., 2024 |
| B | TMB | High | Predictive | Supports | Sensitivity/Response | Lung Non-small Cell Carcinoma | Pembrolizumab | Rizvi et al., 2015 |
| B | TMB | High | Predictive | Supports | Sensitivity/Response | Solid Tumors, Advanced | Immune Checkpoint Inhibitor | Samstein et al., 2019 |
| B | TMB | High | Predictive | Supports | Sensitivity/Response | Lung Non-small Cell Carcinoma | PD1 Inhibitor,PD-L1 Inhibitor | Ricciuti et al., 2022 |
| B | TMB | High | Predictive | Supports | Sensitivity/Response | Lung Non-small Cell Carcinoma | Atezolizumab | Gandara et al., 2018 |
| B | TMB | High | Predictive | Supports | Sensitivity/Response | Solid Tumor | Pembrolizumab | Cristescu et al., 2018 |
| B | TMB | High | Predictive | Supports | Sensitivity/Response | Lung Adenocarcinoma | Ipilimumab/Nivolumab Regimen | Hellmann et al., 2018 |
| B | TMB | H-bTMB | Predictive | Supports | Sensitivity/Response | Lung Non-small Cell Carcinoma | Immune Checkpoint Inhibitor | Wang et al., 2019 |
| B | TMB | High | Predictive | Supports | Sensitivity/Response | Lung Non-small Cell Carcinoma | Toripalimab,Chemotherapy | Xu et al., 2024 |
| B | TMB | High | Predictive | Supports | Sensitivity/Response | Lung Non-small Cell Carcinoma | Ipilimumab/Nivolumab Regimen | Ready et al., 2019 |
| B | TMB | High | Predictive | Supports | Sensitivity/Response | Lung Non-small Cell Carcinoma | Durvalumab/Tremelimumab Regimen | Rizvi et al., 2020 |
| B | TMB | High | Predictive | Supports | Sensitivity/Response | Colorectal Cancer | Pembrolizumab | Schrock et al., 2019 |